UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 4,784 Shares of Glaukos Corporation $GKOS

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its position in shares of Glaukos Corporation (NYSE:GKOS) by 3.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 138,990 shares of the medical instruments supplier’s stock after selling 4,784 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Glaukos were worth $19,425,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of GKOS. AQR Capital Management LLC lifted its holdings in Glaukos by 2.6% in the first quarter. AQR Capital Management LLC now owns 7,788 shares of the medical instruments supplier’s stock valued at $766,000 after buying an additional 198 shares during the period. Jones Financial Companies Lllp grew its holdings in Glaukos by 1,405.9% during the 1st quarter. Jones Financial Companies Lllp now owns 2,560 shares of the medical instruments supplier’s stock worth $252,000 after acquiring an additional 2,390 shares during the period. M&T Bank Corp acquired a new stake in Glaukos during the 2nd quarter worth about $203,000. Gamco Investors INC. ET AL raised its position in shares of Glaukos by 10.7% in the 2nd quarter. Gamco Investors INC. ET AL now owns 8,001 shares of the medical instruments supplier’s stock worth $826,000 after acquiring an additional 773 shares in the last quarter. Finally, State Street Corp raised its position in shares of Glaukos by 5.3% in the 2nd quarter. State Street Corp now owns 2,090,365 shares of the medical instruments supplier’s stock worth $215,914,000 after acquiring an additional 105,972 shares in the last quarter. Institutional investors own 99.04% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on GKOS shares. Citigroup upped their target price on Glaukos from $175.00 to $188.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Wall Street Zen upgraded Glaukos from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Stifel Nicolaus boosted their price target on Glaukos from $175.00 to $190.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. UBS Group assumed coverage on Glaukos in a report on Tuesday, July 28th. They set a “neutral” rating and a $150.00 price target on the stock. Finally, Needham & Company LLC raised their price objective on shares of Glaukos from $150.00 to $201.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Twelve analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $178.08.

Glaukos Price Performance

Shares of NYSE GKOS opened at $178.20 on Friday. The firm has a market capitalization of $10.51 billion, a P/E ratio of -54.83 and a beta of 0.76. The firm’s 50-day moving average price is $166.72 and its 200-day moving average price is $136.35. The company has a current ratio of 5.04, a quick ratio of 4.46 and a debt-to-equity ratio of 0.10. Glaukos Corporation has a 1-year low of $73.16 and a 1-year high of $191.62.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.07. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%.The company had revenue of $185.61 million during the quarter, compared to the consensus estimate of $150.93 million. During the same period last year, the business posted ($0.24) EPS. The firm’s revenue for the quarter was up 49.6% compared to the same quarter last year. Equities research analysts anticipate that Glaukos Corporation will post -0.32 earnings per share for the current fiscal year.

Insider Transactions at Glaukos

In other Glaukos news, Director Gilbert Kliman sold 2,500 shares of the stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $190.00, for a total value of $475,000.00. Following the transaction, the director owned 37,406 shares in the company, valued at approximately $7,107,140. This represents a 6.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Leana Wen sold 525 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $167.63, for a total value of $88,005.75. Following the completion of the sale, the director directly owned 21,092 shares of the company’s stock, valued at $3,535,651.96. This trade represents a 2.43% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 113,025 shares of company stock worth $19,600,006 in the last three months. Insiders own 5.90% of the company’s stock.

Glaukos Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.